Synexus has further strengthened its leadership position in Poland with the acquisition of Osteomed, for an undisclosed sum. Based in Warsaw, Medical Centre Osteomed is a well established and highly respected clinical research company, FDA audited, whose client list includes many of the world's leading pharmaceutical companies and CROs.
Dr Ian Smith was awarded an MBE ‘for services to Health Research' in the Queen's New Years honours list.
Synexus has recently formed two therapeutic advisory boards in respiratory and cardiac medicine. Professor John Kastelein, who is Professor of Medicine at the Department of Vascular Medicine at the Academic Medical Center (AMC) of the University of Amsterdam, where he holds the Strategic Chair of Genetics of Cardiovascular Disease is chair of the cardiac board. Professor Clive Page, who is the Director of the Sackler Institute of Pulmonary Pharmacology and Joint Head of the Institute of Pharmaceutical Science at King's College London, is chair of the respiratory board.
Synexus' Pretoria clinical research centre has enrolled more patients than any other site across the world in a type 2 diabetes trial for Janssen Pharmaceuticals.
Alan Pilgrim has taken over as Chairman of Synexus from Professor Trevor Jones, CBE, who continues on the board as a director and becomes President of the Synexus' Scientific Advisory Board. Synexus, based in Manchester, is the largest multinational organisation dedicated to the recruitment of patients and running of clinical trials at its own Dedicated Research Centres.
Synexus, which confidently expects to sign a record amount of new business this year, has expanded its therapeutic offering to its pharma and CROs clients across the world and further strengthened its board. Synexus, based in Manchester, UK, is the largest multinational organisation dedicated to the recruitment of patients and running of clinical trials at its own Dedicated Research Centres across the globe.
Follow Synexus on Twitter
Back to top ^
